1
|
Romeo R, Legnani L, Chiacchio MA, Giofrè SV, Iannazzo D. Antiviral Compounds to Address Influenza Pandemics: An Update from 2016-2022. Curr Med Chem 2024; 31:2507-2549. [PMID: 37691217 DOI: 10.2174/0929867331666230907093501] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2023] [Revised: 07/11/2023] [Accepted: 07/24/2023] [Indexed: 09/12/2023]
Abstract
In recent decades, the world has gained experience of the dangerous effects of pandemic events caused by emerging respiratory viruses. In particular, annual epidemics of influenza are responsible for severe illness and deaths. Even if conventional influenza vaccines represent the most effective tool for preventing virus infections, they are not completely effective in patients with severe chronic disease and immunocompromised and new small molecules have emerged to prevent and control the influenza viruses. Thus, the attention of chemists is continuously focused on the synthesis of new antiviral drugs able to interact with the different molecular targets involved in the virus replication cycle. To date, different classes of influenza viruses inhibitors able to target neuraminidase enzyme, hemagglutinin protein, Matrix-2 (M2) protein ion channel, nucleoprotein or RNAdependent RNA polymerase have been synthesized using several synthetic strategies comprising the chemical modification of currently used drugs. The best results, in terms of inhibitory activity, are in the nanomolar range and have been obtained from the chemical modification of clinically used drugs such as Peramivir, Zanamivir, Oseltamir, Rimantadine, as well as sialylated molecules, and hydroxypyridinone derivatives. The aim of this review is to report, covering the period 2016-2022, the most recent routes related to the synthesis of effective influenza virus inhibitors.
Collapse
Affiliation(s)
- Roberto Romeo
- Dipartimento di Scienze Chimiche, Biologiche, Farmaceutiche ed Ambientali, Università di Messina, Viale F. Stagno D'Alcontres, Messina, 98166, Italy
| | - Laura Legnani
- Dipartimento di Biotecnologie e Bioscienze, Università di Milano-Bicocca, Piazza della Scienza 2, Milano, 20126, Italy
| | - Maria Assunta Chiacchio
- Dipartimento di Scienze del Farmaco e della Salute, Università di Catania, Viale A. Doria 6, Catania, 95125, Italy
| | - Salvatore V Giofrè
- Dipartimento di Scienze Chimiche, Biologiche, Farmaceutiche ed Ambientali, Università di Messina, Viale F. Stagno D'Alcontres, Messina, 98166, Italy
| | - Daniela Iannazzo
- Dipartimento di Ingegneria, Università di Messina, Contrada di Dio, Messina, 98166, Italy
| |
Collapse
|
2
|
Oriola AO, Oyedeji AO. Essential Oils and Their Compounds as Potential Anti-Influenza Agents. MOLECULES (BASEL, SWITZERLAND) 2022; 27:molecules27227797. [PMID: 36431899 PMCID: PMC9693178 DOI: 10.3390/molecules27227797] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 10/19/2022] [Revised: 11/07/2022] [Accepted: 11/08/2022] [Indexed: 11/16/2022]
Abstract
Essential oils (EOs) are chemical substances, mostly produced by aromatic plants in response to stress, that have a history of medicinal use for many diseases. In the last few decades, EOs have continued to gain more attention because of their proven therapeutic applications against the flu and other infectious diseases. Influenza (flu) is an infectious zoonotic disease that affects the lungs and their associated organs. It is a public health problem with a huge health burden, causing a seasonal outbreak every year. Occasionally, it comes as a disease pandemic with unprecedentedly high hospitalization and mortality. Currently, influenza is managed by vaccination and antiviral drugs such as Amantadine, Rimantadine, Oseltamivir, Peramivir, Zanamivir, and Baloxavir. However, the adverse side effects of these drugs, the rapid and unlimited variabilities of influenza viruses, and the emerging resistance of new virus strains to the currently used vaccines and drugs have necessitated the need to obtain more effective anti-influenza agents. In this review, essential oils are discussed in terms of their chemistry, ethnomedicinal values against flu-related illnesses, biological potential as anti-influenza agents, and mechanisms of action. In addition, the structure-activity relationships of lead anti-influenza EO compounds are also examined. This is all to identify leading agents that can be optimized as drug candidates for the management of influenza. Eucalyptol, germacrone, caryophyllene derivatives, eugenol, terpin-4-ol, bisabolene derivatives, and camphecene are among the promising EO compounds identified, based on their reported anti-influenza activities and plausible molecular actions, while nanotechnology may be a new strategy to achieve the efficient delivery of these therapeutically active EOs to the active virus site.
Collapse
|
3
|
Yarovaya OI, Shcherbakov DN, Borisevich SS, Sokolova AS, Gureev MA, Khamitov EM, Rudometova NB, Zybkina AV, Mordvinova ED, Zaykovskaya AV, Rogachev AD, Pyankov OV, Maksyutov RA, Salakhutdinov NF. Borneol Ester Derivatives as Entry Inhibitors of a Wide Spectrum of SARS-CoV-2 Viruses. Viruses 2022; 14:v14061295. [PMID: 35746766 PMCID: PMC9228966 DOI: 10.3390/v14061295] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2022] [Revised: 06/08/2022] [Accepted: 06/10/2022] [Indexed: 12/13/2022] Open
Abstract
In the present work we studied the antiviral activity of the home library of monoterpenoid derivatives using the pseudoviral systems of our development, which have glycoproteins of the SARS-CoV-2 virus strains Wuhan and Delta on their surface. We found that borneol derivatives with a tertiary nitrogen atom can exhibit activity at the early stages of viral replication. In order to search for potential binding sites of ligands with glycoprotein, we carried out additional biological tests to study the inhibition of the re-receptor-binding domain of protein S. For the compounds that showed activity on the pseudoviral system, a study using three strains of the infectious SARS-CoV-2 virus was carried out. As a result, two leader compounds were found that showed activity on the Wuhan, Delta, and Omicron strains. Based on the biological results, we searched for the potential binding site of the leader compounds using molecular dynamics and molecular docking methods. We suggested that the compounds can bind in conserved regions of the central helices and/or heptad repeats of glycoprotein S of SARS-CoV-2 viruses.
Collapse
Affiliation(s)
- Olga I. Yarovaya
- Department of Medicinal Chemistry, N.N. Vorozhtsov Novosibirsk Institute of Organic Chemistry SB RAS, Lavrentiev ave., 9, 630090 Novosibirsk, Russia; (A.S.S.); (E.D.M.); (A.D.R.); (N.F.S.)
- Correspondence:
| | - Dmitriy N. Shcherbakov
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Koltsovo, Russia; (D.N.S.); (N.B.R.); (A.V.Z.); (A.V.Z.); (O.V.P.); (R.A.M.)
| | - Sophia S. Borisevich
- Laboratory of Chemical Physics Ufa Institute of Chemistry, Ufa Federal Research Center, RAS, Octyabrya pr., 71, 450054 Ufa, Russia; (S.S.B.); (E.M.K.)
| | - Anastasiya S. Sokolova
- Department of Medicinal Chemistry, N.N. Vorozhtsov Novosibirsk Institute of Organic Chemistry SB RAS, Lavrentiev ave., 9, 630090 Novosibirsk, Russia; (A.S.S.); (E.D.M.); (A.D.R.); (N.F.S.)
| | - Maxim A. Gureev
- Research Center “Digital Biodesign and Personalized Healthcare”, I.M. Sechenov First Moscow State Medical University, Trubetskaya str., 8/2, 119991 Moscow, Russia;
- Department of Computational Biology, Sirius University of Science and Technology, Olympic Ave., 1, 354340 Sochi, Russia
| | - Edward M. Khamitov
- Laboratory of Chemical Physics Ufa Institute of Chemistry, Ufa Federal Research Center, RAS, Octyabrya pr., 71, 450054 Ufa, Russia; (S.S.B.); (E.M.K.)
| | - Nadezda B. Rudometova
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Koltsovo, Russia; (D.N.S.); (N.B.R.); (A.V.Z.); (A.V.Z.); (O.V.P.); (R.A.M.)
| | - Anastasiya V. Zybkina
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Koltsovo, Russia; (D.N.S.); (N.B.R.); (A.V.Z.); (A.V.Z.); (O.V.P.); (R.A.M.)
| | - Ekaterina D. Mordvinova
- Department of Medicinal Chemistry, N.N. Vorozhtsov Novosibirsk Institute of Organic Chemistry SB RAS, Lavrentiev ave., 9, 630090 Novosibirsk, Russia; (A.S.S.); (E.D.M.); (A.D.R.); (N.F.S.)
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Koltsovo, Russia; (D.N.S.); (N.B.R.); (A.V.Z.); (A.V.Z.); (O.V.P.); (R.A.M.)
| | - Anna V. Zaykovskaya
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Koltsovo, Russia; (D.N.S.); (N.B.R.); (A.V.Z.); (A.V.Z.); (O.V.P.); (R.A.M.)
| | - Artem D. Rogachev
- Department of Medicinal Chemistry, N.N. Vorozhtsov Novosibirsk Institute of Organic Chemistry SB RAS, Lavrentiev ave., 9, 630090 Novosibirsk, Russia; (A.S.S.); (E.D.M.); (A.D.R.); (N.F.S.)
| | - Oleg V. Pyankov
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Koltsovo, Russia; (D.N.S.); (N.B.R.); (A.V.Z.); (A.V.Z.); (O.V.P.); (R.A.M.)
| | - Rinat A. Maksyutov
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Koltsovo, Russia; (D.N.S.); (N.B.R.); (A.V.Z.); (A.V.Z.); (O.V.P.); (R.A.M.)
| | - Nariman F. Salakhutdinov
- Department of Medicinal Chemistry, N.N. Vorozhtsov Novosibirsk Institute of Organic Chemistry SB RAS, Lavrentiev ave., 9, 630090 Novosibirsk, Russia; (A.S.S.); (E.D.M.); (A.D.R.); (N.F.S.)
| |
Collapse
|